Enasidenib
About
Therapy type: Targeted therapy
Therapy strategy: IDH2 inhibition
Mappings
NCI Thesaurus: Enasidenib (ncit:C111573)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | IDH2 p.R140Q | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R140L | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R140G | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R140W | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R172K | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R172M | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R172G | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R172S | Acute Myeloid Leukemia | Enasidenib | |
| FDA (1) | IDH2 p.R172W | Acute Myeloid Leukemia | Enasidenib |